Health economics modelling for biotech and pharma — faster, leaner, and at a fraction of large consultancy fees.
A partner sells it in. A junior analyst builds it. Timelines slip. Fees grow. The model arrives over-engineered for the decision it was built to support. Biotech and pharma companies deserve better.
Formulary submissions, payer negotiations, and managed entry agreements — adapted for individual payer and market requirements across the UK, Europe, and US.
Learn more →Disease burden evidence that frames the unmet need, shapes the market, and gives payers and investors the context they need to act.
Learn more →Submission-quality models built to the requirements of NICE, SMC, AWMSG, G-BA, HAS, CADTH, and other major HTA bodies.
Learn more →Credible patient population sizing across geographies — the foundation every other model is built on, calibrated to local data sources.
Learn more →Pathway costing and current care benchmarking calibrated to local healthcare systems and payer expectations across global markets.
Learn more →Global suites connecting burden, population, and economic evidence into a single market access narrative — built to travel across markets.
Learn more →Your project is led and built by experienced health economists — not handed off to junior staff supervised from a distance. You get the expertise you're paying for.
Deep familiarity with HTA requirements and payer expectations across the US, UK, Europe, and beyond. We know what NICE, G-BA, HAS, and CADTH need to see — and how to build models that stand up to scrutiny.
We build the model the decision requires — not the model that justifies the engagement. If a decision tree is the right tool, we'll tell you, even if a Markov model would have cost more.
Every project is priced upfront. Clear scope, agreed timeline, no time-and-materials billing that grows with every revision request.
Our global models are architected from the outset for local adaptation — protecting your investment as you move across markets without rebuilding from scratch.
Tell us about your indication, your markets, and your timeline.
We'll come back to you within one working day.